Expert Interview
Understanding the impact of Eylea biosimilars on the wet-AMD market
Ticker(s): REGN, RHHBY, AMGNInstitution: Elman Retina Group
- Ophthalmologist in private practice
- Specializes in surgical and medical care of retinal and vitreous diseases, such as macular degeneration, diabetic retinopathy and edema, and retinal detachments; sees 200-300 patients a week
- Authored multiple research articles in leading ophthalmology journals, as well as retinal textbook chapters
Roughly how many patients do you manage with wet amd?
Added By: ben_adminHow many are on Eylea? Eylea HD?
Added By: ben_adminHow impactful has the approval of Eylea HD been on the treatment of your patients?
Added By: ben_adminHave you prescribed an Eylea biosimilar? If not why?
Does an Eylea biosimilar from a large company like Amgen make it more appealing?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
